αβ,α′β′-Diepoxyketones are mechanism-based inhibitors of nucleophilic cysteine enzymes

被引：2

作者：

de Munnik, Mariska ^{[1
,2
]}

Lithgow, Jasper ^{[1
,2
]}

Brewitz, Lennart ^{[1
,2
]}

Christensen, Kirsten E. ^{[3
]}

Bates, Robert H. ^{[4
]}

Rodriguez-Miquel, Beatriz ^{[4
]}

Schofield, Christopher J. ^{[1
,2
]}

机构：

[1] Univ Oxford, Dept Chem, Chem Res Lab, 12 Mansfield Rd, Oxford OX1 3TA, England

[2] Univ Oxford, Ineos Oxford Inst Antimicrobial Res, 12 Mansfield Rd, Oxford OX1 3TA, England

[3] Univ Oxford, Dept Chem, Chem Res Lab, Chem Crystallog, 12 Mansfield Rd, Oxford OX1 3TA, England

[4] GlaxoSmithKline, Tres Cantos Med Dev Campus, Calle Severo Ochoa 2, Madrid, Spain

来源：

CHEMICAL COMMUNICATIONS | 2023年 / 59卷 / 86期

关键词：

IRREVERSIBLE INHIBITORS; PROTEASOME INHIBITOR; BETA-LACTAMASE; INACTIVATION; LDT(MT2); BINDING; DISCOVERY; PROTEINS; REVEALS;

D O I：

10.1039/d3cc02932h

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Epoxides are an established class of electrophilic alkylating agents that react with nucleophilic protein residues. We report alpha beta,alpha 'beta '-diepoxyketones (DEKs) as a new type of mechanism-based inhibitors of nucleophilic cysteine enzymes. Studies with the l,d-transpeptidase LdtMt2 from Mycobacterium tuberculosis and the main protease from SARS-CoV-2 (Mpro) reveal that following epoxide ring opening by a nucleophilic cysteine, further reactions can occur, leading to irreversible alkylation. alpha beta,alpha 'beta '-Diepoxyketones (DEKs) inhibit nucleophilic cysteine enzymes. DEKs react with a transpeptidase and the SARS-CoV-2 main protease via epoxide opening; retro-aldol and other reactions can then occur, enabling irreversible alkylation.

引用

页码：12859 / 12862

页数：4

共 50 条

[31] DESIGN AND EVALUATION OF MECHANISM-BASED INHIBITORS OF DIAMINE OXIDASE
TOBES, MC
GRIFFITH, RK
DIPIETRO, RA
ZOOROB, HH
FEDERATION PROCEEDINGS, 1983, 42 (07) : 2042 - 2042
[32] Kinetic characterization and optimization of mechanism-based inhibitors of BioA
Eiden, Carter
Aldrich, Courtney
Lipscomb, John
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
[33] THE INTERACTION OF MECHANISM-BASED INHIBITORS WITH MONOAMINE-OXIDASE
ANDERSON, MC
BACKWELL, C
WILLIAMS, CH
TIPTON, KF
BIOCHEMICAL SOCIETY TRANSACTIONS, 1987, 15 (02) : 244 - 245
[34] HDAC inhibitors: Clinical update and mechanism-based potential
Glaser, Keith B.
BIOCHEMICAL PHARMACOLOGY, 2007, 74 (05) : 659 - 671
[35] Novel, selective mechanism-based inhibitors of the herpes proteases
Pinto, IL
West, A
Debouck, CM
DiLella, AG
Gorniak, JG
ODonnell, KC
OShannessy, DJ
Patel, A
Jarvest, RL
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (20) : 2467 - 2472
[36] MECHANISM-BASED INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE
VILLAFRANCA, JJ
COLOMBO, G
RAJASHEKHER, B
FITZPATRICK, P
FLORY, D
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1984, 188 (AUG): : 108 - BIOL
[37] MECHANISM-BASED INHIBITORS OF DOPAMINE BETA-HYDROXYLASE
FITZPATRICK, PF
VILLAFRANCA, JJ
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1987, 257 (02) : 231 - 250
[38] MECHANISM-BASED INHIBITORS OF DOPAMINE BETA-HYDROXYLASE
VILLAFRANCA, JJ
COLOMBO, G
RAJASHEKHER, B
FITZPATRICK, P
FLORY, D
BIOCHEMISTRY, 1984, 23 (14) : 3366 - 3366
[39] ON THE DEFINITION AND CLASSIFICATION OF MECHANISM-BASED ENZYME-INHIBITORS
PRATT, RF
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1992, 2 (11) : 1323 - 1326
[40] Mechanism-based inhibitors - the new phenomenon in enzymology and biology
Pec, P
Frebort, I
Sebela, M
CHEMICAL PAPERS, 1998, 52 : 331 - 331

← 1 2 3 4 5 →